NCT06340893 Exercise Training in Children With Communication Impairments
| NCT ID | NCT06340893 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Marquette University |
| Condition | Developmental Language Disorder |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2024-07-02 |
| Primary Completion | 2025-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 40 participants in total. It began in 2024-07-02 with a primary completion date of 2025-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This clinical trial study has two goals. The first goal is to establish fitness levels, participation in physical activities, and fine/gross motor abilities for children with development language disorder (DLD). DLD occurs in 1/13 children and children with DLD often have poorer fine/gross motor skills than those with typical development. The second goal is to determine whether physical exercise helps children with DLD and typical development to learn better and improve fitness and fine/gross motor abilities more than participating in restful play activities. All children (DLD and typically developing) will undergo communication, fine/gross motor and fitness testing. Children will be randomly assigned to participate in an exercise program (n =20) or to a restful play program (n = 20). Both programs will take place 3x/week for 6 weeks and children will only participate in one of the two programs. Children in the exercise program will do activities to train cardiovascular fitness, agility, balance, strength, and endurance while children in the restful play condition will do things like play with legos and color. Researchers will compare changes in learning tasks and fitness levels for children (DLD and typically developing) who participated in the exercise program vs. restful play program.
Eligibility Criteria
Inclusion Criteria: Children with a diagnosis of developmental language disorder (DLD) or typically developing controls will be included. All children will meet following inclusion criteria: * (1) between 5 and 9 years old at enrollment * (2) from homes where the primary language spoken is English * (3) normal hearing based on parent report and audiometric screening * (4) typical nonverbal cognition as determined by a T-score within 1.5 standard deviations of the mean on nonverbal subtests of the Reynolds Intellectual Assessment Scales Exclusion Criteria: Exclusionary Criteria are: * (1) diagnosis of disorder that significantly affects social interactions (e.g., autism), as per referral diagnosis or which is identified during initial screening or assessment phase * (2) vision impairments that prevent participation in our experimental protocol * (3) inability for any reason to participate in assessment and/or treatment protocols
Contact & Investigator
Jenya Iuzzini-Seigel, PhD
PRINCIPAL INVESTIGATOR
Marquette University
Frequently Asked Questions
Who can join the NCT06340893 clinical trial?
This trial is open to participants of all sexes, aged 5 Years or older, up to 9 Years, studying Developmental Language Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06340893 currently recruiting?
Yes, NCT06340893 is actively recruiting participants. Contact the research team at jenya.iuzzini-seigel@marquette.edu for enrollment information.
Where is the NCT06340893 trial being conducted?
This trial is being conducted at Milwaukee, United States.
Who is sponsoring the NCT06340893 clinical trial?
NCT06340893 is sponsored by Marquette University. The principal investigator is Jenya Iuzzini-Seigel, PhD at Marquette University. The trial plans to enroll 40 participants.